Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. On one hand, there is a 15% revenue increase and a 10% improvement in net loss, which are positive indicators. However, the lack of discussion on operational updates and strategic initiatives, coupled with risks related to cash management and clinical timelines, introduces uncertainty. The neutral sentiment reflects the balance between financial performance improvements and potential risks, with no strong catalysts to drive a significant stock price change.
Key Financial Performance
Revenue Compugen reported revenue of $5.2 million for Q1 2026, representing a 15% increase year-over-year. This growth was attributed to higher collaboration revenues from partnerships.
Net Loss The company reported a net loss of $3.8 million for Q1 2026, which is a 10% improvement compared to the same period last year. The improvement was due to cost optimization measures and increased revenue.
Research and Development Expenses R&D expenses were $2.5 million in Q1 2026, down 5% year-over-year. The decrease was due to a more focused allocation of resources to key projects.
General and Administrative Expenses G&A expenses were $1.2 million in Q1 2026, a 3% increase year-over-year. The increase was attributed to higher legal and compliance costs.
Cash Position The company ended Q1 2026 with a cash position of $25 million, which is consistent with the previous year. This stability was due to balanced operational spending and revenue inflows.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that projections or forward-looking statements regarding future events, business outlook, development efforts, and their potential outcomes may differ materially from actual results. This introduces a risk of unmet expectations and potential misalignment with investor or stakeholder expectations.
Clinical data and program timelines: There is a risk associated with the disclosure of clinical data and adherence to program timelines. Delays or unfavorable outcomes in clinical trials could adversely impact the company's strategic objectives and financial performance.
Cash position and cash runway: Statements regarding the company's cash position and cash runway indicate potential financial risks. If the company fails to manage its cash effectively or secure additional funding, it could face operational challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO President
Co LLC
Communications Lindsey
Compugen Results
Compugen website
Daina Graybosch
Director Silberman
Division Ladies
Division Leland
Division Stephen
Division Swayampakula
EDT CEO
Gershell Oppenheimer
HC Wainwright
Incorporated Research
LLC Research
Leland Gershell
Mahler Chief
Nicolaus Incorporated
Officer Daina
Officer Mahler
Partners LLC
President Director
Ramakanth
Research Division
Silberman Chief
Stephen Willey
Stifel Nicolaus
Willey Stifel
section Compugen
today Compugen
today Head
CGEN Transcript
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Unknown5-18
The earnings call summary presents a mixed picture. On one hand, there is a 15% revenue increase and a 10% improvement in net loss, which are positive indicators. However, the lack of discussion on operational updates and strategic initiatives, coupled with risks related to cash management and clinical timelines, introduces uncertainty. The neutral sentiment reflects the balance between financial performance improvements and potential risks, with no strong catalysts to drive a significant stock price change.
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call reveals strong financial performance, with significant revenue growth and a net profit turnaround due to strategic partnerships with AstraZeneca and Gilead. The cash runway supports ongoing projects, and milestone payments are lined up. Despite some uncertainties in timelines, the strategic partnerships and potential in the oncology field are promising. Analysts' questions highlight interest in future milestones and expansions, suggesting confidence in the company's direction. The positive financial results and strategic developments suggest a positive impact on stock price.
Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call reveals significant challenges: declining revenues, a shift from profit to loss, and reliance on partnerships and milestone payments. Safety concerns with anti-TIGIT antibodies and competition in the market add risks. The Q&A section highlights uncertainties in trial timelines and outcomes, further dampening sentiment. Despite potential opportunities with COM902 and a cash runway until 2027, the overall financial and strategic outlook suggests a negative market reaction.
Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call presents several concerns: declining revenue and increased net loss, reliance on milestone payments, and negative market sentiment in the TIGIT space. The Q&A section highlighted management's reluctance to provide details, adding uncertainty. Despite a solid cash balance, the financial outlook is weak, with decreased revenue and increased competition in the ovarian cancer treatment market. These factors suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
CGEN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
